Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma - PubMed
2 days ago
- #immunotherapy
- #PD-L1
- #osteosarcoma
- Allicin inhibits PD-L1 expression via the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.
- Study used GEO database for gene screening and identified IL-6/JAK2/STAT3/PDL1 pathway via KEGG and GO analysis.
- HOS human and K7M2 mouse osteosarcoma cell lines treated with allicin (12.5, 25, 50 μmol/L) showed reduced growth, migration, and invasion.
- Western Blot confirmed downregulation of IL-6/JAK2/STAT3 pathway and PD-L1 in allicin-treated cells.
- In vivo studies in Balb/c mice showed increased CD4+ and CD8+ T cells, higher IFN-γ and granzyme B, and reduced tumor immune evasion.
- Allicin improves tumor microenvironment and inhibits immune evasion, suggesting its potential as an immunotherapy adjunct.